FreeTheAI

Interpace Biosciences Expects Up to 18% Q3 Revenue Growth

MixedMedium impact
IDXG$5.52 −6.47%

Interpace Biosciences, Inc. (OTC:IDXG) expects third-quarter 2026 revenue to range between $10.1 million and $10.4 million, based on preliminary and unaudited financial estimates. The projected range represents an increase of 11% to 14% compared to $9.1 million in the second quarter of 2026, and a gain of 15% to 18% compared to $8.8 million in the third quarter of 2025.

The molecular diagnostics company specializes in personalized medicine through diagnostic tests, including ThyGeNEXT and ThyraMIR v2, which evaluate indeterminate thyroid nodules. Management noted that the financial figures remain subject to quarter-end closing procedures and external accounting firm review, which could lead to adjustments in the final results.

Investors will look ahead to the full third-quarter financial report, which the company expects to publish at a later date. Meanwhile, Interpace Biosciences has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed securities offering. Shares of the company closed down 6.47% at $5.518.

Key points

  • Interpace Biosciences, Inc. (OTC:IDXG) expects Q3 2026 preliminary revenue between $10.1 million and $10.4 million.
  • Revenue is projected to rise 15% to 18% compared to $8.8 million in the third quarter of 2025.
  • Sequential revenue growth is expected to reach 11% to 14% over Q2 2026 revenue of $9.1 million.
  • The financial metrics remain preliminary, unaudited, and subject to quarter-end closing adjustments.
  • The company filed a registration statement with the SEC regarding a securities offering.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is Interpace Biosciences expected Q3 2026 revenue?

Interpace Biosciences expects preliminary third-quarter 2026 revenue to range between $10.1 million and $10.4 million.

How much did Interpace Biosciences revenue grow year over year?

Preliminary Q3 2026 revenue represents a 15% to 18% increase compared to $8.8 million reported in the third quarter of 2025.

What tests does Interpace Biosciences commercialize?

Interpace Biosciences commercializes ThyGeNEXT and ThyraMIR v2, specialized molecular tests used together to evaluate indeterminate thyroid nodules.